Basis: FMP quote market capitalization / four-quarter operating cash flow. Source: stored company filings and market data; unavailable inputs remain N/A.
The Price/OCF ratio is N/A as of 2026-10-06T18:00:57.929Z.
Calculation as of: 2026-10-06T18:00:57.929Z.
Quote observation: 2026-10-06T17:55:36.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: 2c805ffacfcdae638738386c116dc6e6f159143ed75419b2c785d409d5d1ab78
Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
PRICE/OCF RATIO
N/A
Market Cap
$24.13M
Price/OCF Ratio
N/A
TTM Avg
242.89
3Y Avg
242.89
5Y Avg
242.89
Market Cap
$27.21M
Price/OCF Ratio
N/A
TTM Avg
67.48
3Y Avg
67.48
5Y Avg
51.02
| NAME | MARKET CAP | PRICE/OCF RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Atossa Therapeutics, Inc. (ATOS) | $24.94M | N/A | N/A | N/A | N/A |
| InspireMD, Inc. (NSPR)vs › | $25.29M | N/A | N/A | N/A | N/A |
| iTonic Holdings Ltd. (ITOC)vs › | $25.98M | N/A | N/A | N/A | N/A |
| ABVC BioPharma, Inc. (ABVC)vs › | $24.13M | N/A | 242.89 | 242.89 | 242.89 |
| Kyntra Bio, Inc. (KYNB)vs › | $23.92M | N/A | 94.98 | 95.49 | 117.44 |
| TherapeuticsMD, Inc. (TXMD)vs › | $23.26M | 7.46 | 10.70 | 8.47 | 6.22 |
| Rein Therapeutics Inc. (RNTX)vs › | $22.88M | N/A | N/A | N/A | N/A |
| Seres Therapeutics, Inc. (MCRB)vs › | $27.21M | N/A | 67.48 | 67.48 | 51.02 |
| LeonaBio, Inc. (LONA)vs › | $22.54M | N/A | N/A | N/A | N/A |
| aTyr Pharma, Inc. (ATYR)vs › | $27.67M | N/A | N/A | N/A | N/A |
P/OCF Ratio
N/A
P/FCF Ratio
N/A
P/OCF measures market price relative to operating cash flow: market cap divided by TTM operating cash flow. OCF is cash from operations before capital expenditures, so it sits above free cash flow — P/OCF typically reads below P/FCF, with the widest gap for capex-heavy businesses.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
